With Lannett reporting “better than expected financial results” for its financial first quarter – buoyed by stepping in to supply during a major US shortage, as well as a “more favorable pricing environment” for generics (Also see "Lannett Sees Boost From Adderall Shortages And Pricing Reprieve" - Generics Bulletin, 9 November, 2022.) – the firm has also set out its current expectations for some of its major pipeline assets that are expected to drive growth over the coming years, in particular its insulins and respiratory complex generics.
“For both our biosimilar insulin glargine and biosimilar insulin aspart products, timelines remain largely on track,” Lannett CEO Tim Crew indicated as he provided the latest